Elixinol, LLC is facing a class action lawsuit in California that alleges its CBD products are illegally marketed. The complaint claims that Elixinol’s products, including capsules and dog treats, are mislabeled as dietary supplements, which the FDA currently prohibits. The lawsuit argues that these products do not comply with federal regulations due to improper labeling and lack of adequate usage directions. This case highlights ongoing regulatory confusion surrounding CBD, as the FDA continues to grapple with how to appropriately classify and regulate these products.
